A PAK inhibitor selective for group I PAKs (IC50s = 7.7, 12.8, and 19.3 nM for PAK 1, 2, and 3, respectively) over group II PAKs (IC50 > 10 μM for PAK4 and 50 = 70 nM); reduces proliferation and survival of transformed Schwann cells, ovarian, and pancreatic cells; works synergistically with gemcitabine in pancreatic cancer models in vitro and in vivo,